Selurampanel

Cat. No.:	HY-105860
CAS No.:	912574-69-7
Molecular Formula:	$C_{16}H_{19}N_5O_4S$
Molecular Weight:	377.42
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



BIOLOGICAL ACTIVITY

Description	Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC_{50} of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research[1][2].
In Vivo	Selurampanel (Compound 1S) potently and dose-dependently antagonizes maximal electroshock seizure (MES)-induced generalized tonic-clonic seizures in mice with an ED_{50} value around 7 mg/kg after 1 h pre-treatment[1]. In a study with a 3 mg/kg i.v. dose, a mouse plasma half-life of 3.3 h is determined, with a moderate volume of distribution (V_{dss}=1.3 L/kg) and a low clearance of 5.4 mL/min⋅kg[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. David Orain, et al. Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist. ChemMedChem. 2017 Feb 3;12(3):197-201.

[2]. Edward Faught, et al. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA